Laimoud Mohamed H, Raslan Ismail R
Department of Cardiovascular Critical Care, Prince Sultan Cardiac Center, Riyadh 12611, Saudi Arabia.
Critical Care Medicine, Cairo University, Cairo 12613, Egypt.
World J Cardiol. 2024 Nov 26;16(11):665-668. doi: 10.4330/wjc.v16.i11.665.
Sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have been increasingly used with proven efficacy in patients with heart failure (HF), regardless of diabetes status. Grubić Rotkvić recently published an observational study on SGLT2i therapy in patients with type 2 diabetes mellitus and asymptomatic HF. They found that the use of SGLT2i led to reduced cardiac load and improved cardiovascular performance, reinforcing the evolving paradigm that SGLT2i are not merely glucose-lowering agents but are integral to the broader management of cardiovascular risk in patients with type 2 diabetes mellitus. The study by Grubić Rotkvić contributes to the growing body of literature supporting the early use of SGLT2i in patients with diabetic cardiomyopathy, offering a potential strategy to mitigate the progression of HF. Future larger studies should be conducted to confirm these findings, and explore the long-term cardiovascular benefits of SGLT2i, particularly in asymptomatic patients at risk of developing HF.
钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）已越来越多地用于心力衰竭（HF）患者，并已证实具有疗效，无论患者是否患有糖尿病。格鲁比奇·罗特克维奇最近发表了一项关于SGLT2i治疗2型糖尿病和无症状HF患者的观察性研究。他们发现，使用SGLT2i可降低心脏负荷并改善心血管功能，这强化了一种不断发展的模式，即SGLT2i不仅是降糖药物，而且对于2型糖尿病患者心血管风险的更广泛管理至关重要。格鲁比奇·罗特克维奇的研究为支持在糖尿病性心肌病患者中早期使用SGLT2i的文献不断增加做出了贡献，提供了一种减轻HF进展的潜在策略。未来应进行更大规模的研究以证实这些发现，并探索SGLT2i的长期心血管益处，特别是在有发生HF风险的无症状患者中。
